



NanoBiotix to showcase its *NanoTherapeutics* at 'In³ Europe' investor conference in Paris

by Ronald C. Trahan

Paris-based **NanoBiotix** (www.nanobiotix.com) will be one of the “must see” companies at Medtech Insight’s ‘In³ Europe’ conference when its **Co-Founder and CEO Laurent Levy, PhD**, takes the podium on April 29th. “We are dedicated to finding **new treatments for cancer** that are based on the *combined* application of nanotechnologies and biotechnologies, which we call **NanoTherapeutics**,” explains Dr. Levy. “NanoTherapeutics are designed to precisely target abnormal cells and destroy them through the controlled generation of physical or chemical reactions triggered by external activation.” NanoTherapeutics are composed of two parts: (1) an inorganic core which, through external activation (for example, the application of MRI) will cause the destruction of the targeted cells by a purely physical mechanism; and, (2) an inert coating to provide a better biodistribution of the device. “This unique mode of action explains the accuracy of the therapeutic activity and the expected excellent tolerability,” says Dr. Levy. “Furthermore, because the activity is triggered *externally*, this suggests a total control of the activity of the NanoTherapeutics.” **NanoBiotix has demonstrated, *in vitro* and *in vivo*, both the efficacy as well as the tolerability of the NanoTherapeutics currently under development.** Also, *in vitro* and *in vivo* experiments have validated the concept of cell destruction through external activation and the absolute control of this process, along with the emergence of an activation time-cell destruction function. Promising large animal studies on various cancer models related to targeted clinical applications and different compounds are currently under way. The Company also has selected its first product to reach the clinic. NanoBiotix is partnering with the State University of New York (SUNY), where its founders initiated development of this innovative technology within the Institute for Lasers, Photonics and Biophotonics. NanoBiotix holds the rights and patents on a variety of NanoTherapeutics families (MRI-, Laser-, XRay- and Ultrasound-activated). “We are looking forward to telling our story at In³ Europe, because Medtech Insight’s In³ events are no doubt *the* premier medical technology-focused investor meetings in Europe and the US,” says Dr. Levy. ■



LAURENT LEVY, PhD
Co-Founder and CEO,
NanoBiotix

What the Leading Medtech Experts Are Saying about Medtech Insight’s In³ Events:



“Medtech Insight’s In³ meetings provide me with an efficient platform, helping me make the most of my limited time in seeking out potentially disruptive technologies compatible with our investing objectives and criteria.”

Christian Sarwa
Investment Manager
NBGI Ventures
London, England



“The plenary sessions at Medtech Insight conferences permit attendees to reap priceless know-how from device industry captains who share ‘in the trenches’ experiences in building, funding and selling their companies.”

Anthony Coia, MD
Associate
BioVentures Investors
Cambridge, MA



“Medtech Insight conferences have afforded us the opportunity to invest in two great companies to date as a direct result of our participation at In³ conferences. There are very few meetings of such consistently high quality in the medtech sector.”

Christophe Douat
Partner
Maignon Technologies
Paris, France

Investment In Innovation (In³) Europe:

**Bridging European and U.S. Medical Device Innovators, Investors and Companies
Medtech Insight’s 30th Investment & Partnering Event!
The Hilton Paris, April 29-30, 2008**

Medtech Insight’s conferences have drawn over **7,200** attendees and more than **1,350** innovative, presenting companies during the past **8** years—making them *the* premier investment, partnering, and networking event in the medical technology industry. *In³ Europe* will feature a new group of over 30 early- to late-stage medical technology companies seeking partnering and/or investment.

To register for this conference, please call **Kristy Grimes** at **480-985-9512** or **888-202-5939** (toll-free in the U.S.), or email in3@windhover.com.

Ronald C. Trahan is President/CEO of Ronald Trahan Associates Inc. (www.ronaldtrahan.com), a public relations/investor relations firm that serves big and small medtech companies, both public and private.